Rankings · Capital
Insiders buying
Companies whose directors, officers and largest holders bought more shares on the open market than they sold over the last twelve months, from SEC Form 4 filings, ranked by the net amount bought. Share grants and option exercises are left out.
49 companies meet this test
Figures as of September 30, 2026
| # | Company | Grade | Net bought by insiders | Insiders buying | Market value |
|---|---|---|---|---|---|
| 1 | IMVTIMMUNOVANT, INC. | not rated | $348.2M | 1 | $6.9B |
| 2 | AKTSAktis Oncology, Inc. | not rated | $114.3M | 6 | $1B |
| 3 | KYMRKYMERA THERAPEUTICS, INC. | D- | $101.9M | 1 | $9.2B |
| 4 | SNDASONIDA SENIOR LIVING, INC. | D | $100M | 1 | $1.8B |
| 5 | STAASTAAR Surgical Co | C | $62.8M | 2 | $1.1B |
| 6 | KODKODIAK SCIENCES INC. | not rated | $60M | 1 | $5.7B |
| 7 | MANEVeradermics, Inc | not rated | $58.1M | 5 | $4.9B |
| 8 | GENBGenerate Biomedicines, Inc. | not rated | $50.3M | 6 | $2B |
| 9 | BHVNBiohaven Ltd. | not rated | $30.6M | 4 | $2B |
| 10 | ZBIOZenas BioPharma, Inc. | F- | $23.8M | 7 | $1.7B |
More rankings
A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.